论文部分内容阅读
近十年小儿急性淋巴细胞白血病(ALL)的治疗方案已显著延长了生存期,现在这些患儿在停止化学药物治疗后,数年内一直处于病情缓解,因此研究这些患儿治疗后的远期免疫状态已成为重要课题。本文作者对40例普通型ALL小儿进行了免疫方面研究。观察时患儿年龄为5～17岁。他们停止治疗已达4周～5年(平均1.9年)。8例以前曾有中枢神经系统或骨髓复发。全部病例接受过脑部放射治疗,其中8例还同时行脊髓照射。所有病人应用过强的松、长春新硷、氨甲喋呤、6巯基嘌呤。多数病人还用过阿
The treatment of pediatric acute lymphoblastic leukemia (ALL) for the past 10 years has significantly prolonged survival. Now that these children have been in remission after stopping chemical therapy for several years, the long-term immunization after treatment of these children is studied. State has become an important issue. The authors studied 40 cases of children with common ALL. Observed children aged 5 to 17 years old. They stopped treatment for 4 weeks to 5 years (average 1.9 years). Eight patients had previous relapses of the central nervous system or bone marrow. All cases received brain radiotherapy, and 8 of them also received spinal cord irradiation. All patients had used prednisone, vinorelbine, methotrexate, and 6-mercaptopurine. Most patients also used Azerbaijan.